— February 26, 2026 · Oral Semaglutide and the Heart in Type 2 Diabetes

A new analysis of one of the largest diabetes drug trials ever run suggests that the pill form of semaglutide — the same medicine sold as an injection under names like Ozempic — may protect the heart in a specific group of people: those who already have heart failure. The result is genuinely encouraging, but it comes with important limits, and understanding both halves matters more than the headline.

The Finding
What Oral Semaglutide Is
What the Trial Actually Showed
Who It Helps — and Who It Doesn't
The Honest Caveats
Practical Takeaway
Sources
Connections
Featured Videos

The Finding

On February 26, 2026, researchers led by senior author Rodica Pop-Busui, M.D., Ph.D. (now at Oregon Health & Science University) reported in JAMA Internal Medicine that daily oral semaglutide lowered the risk of heart-failure events in people with type 2 diabetes who already had a history of heart failure. Among that subgroup, the drug cut the combined risk of heart-failure hospitalization, urgent heart-failure visits, and cardiovascular death by roughly 22% compared with placebo — and it did so without raising the rate of serious side effects. It is a reassuring result for a group of patients who have historically been treated with caution.

What Oral Semaglutide Is

Semaglutide is a GLP-1 receptor agonist — a class of medicines that mimic a gut hormone the body releases after eating. GLP-1 drugs lower blood sugar, slow the emptying of the stomach, quiet appetite, and, in several large trials, protect the heart and kidneys. Most people know semaglutide as a weekly injection (Ozempic, Wegovy). The version studied here is the once-daily tablet, taken first thing in the morning on an empty stomach, dosed up in steps of 3 mg, then 7 mg, then 14 mg.

The data come from a large study called SOUL (the Semaglutide Cardiovascular Outcomes trial), which enrolled roughly 9,650 adults who had type 2 diabetes plus established heart or blood-vessel disease and/or chronic kidney disease. Participants were followed for a mean of about four years (47.5 months). The main SOUL result had already shown fewer major cardiovascular events overall. This new report is a closer look at one piece of that picture: heart failure.

What the Trial Actually Showed

Of the roughly 9,650 participants, 2,229 (about 23%) had a history of heart failure when they entered the trial. Within that group, the numbers were meaningful:

People with prior heart failure: oral semaglutide was associated with a 22% lower risk of the combined heart-failure outcome (hazard ratio 0.78; 95% confidence interval 0.63–0.96). Because the confidence interval stays below 1.0, this reached statistical significance.
The benefit clustered in one type of heart failure. Among people with HFpEF — heart failure with preserved ejection fraction, where the heart muscle stiffens rather than weakens — the reduction was larger (hazard ratio 0.59; 95% CI 0.39–0.86). Among people with reduced ejection fraction (HFrEF), there was no measurable benefit (hazard ratio 0.98).
People without heart failure at baseline saw no heart-failure benefit (hazard ratio 1.01). The drug neither helped nor harmed them on this particular outcome.
Safety was reassuring. In the heart-failure group, serious adverse events were actually slightly lower on semaglutide (53.8%) than on placebo (57.1%) — addressing a longstanding worry that GLP-1 drugs might be risky in fragile heart-failure patients.

In plain terms: the pill did not create a new heart benefit out of thin air for everyone. It sharpened an existing one for the people who needed it most — and it did so safely.

Who It Helps — and Who It Doesn't

If you have type 2 diabetes and established heart failure — particularly the preserved-ejection-fraction (HFpEF) kind — this study is good news. It suggests the oral GLP-1 option is not only safe for you but may reduce hospitalizations and cardiovascular death. For the many people who dislike or cannot manage weekly injections, having a pill with this kind of evidence behind it genuinely widens the menu of choices.

If you have diabetes but no heart failure, this particular result is not a reason to start semaglutide for heart protection; the study found no heart-failure benefit in that group. And if your heart failure is the reduced-ejection-fraction (HFrEF) type, the signal was flat — the well-established HFrEF medicines (such as SGLT2 inhibitors, which have strong dedicated trials) remain the priority there.

The Honest Caveats

Several things keep this from being a settled recommendation:

It was a secondary analysis. SOUL was designed to test overall cardiovascular events, not heart failure specifically. Findings pulled out of subgroups after the fact are best read as strongly suggestive, not proof. They generate the hypothesis that a future, purpose-built trial should confirm.
The strongest signal came from a small slice. The impressive HFpEF result rested on fewer than 1,000 people. Smaller numbers mean wider uncertainty, and the effect could shrink when tested head-on.
The pill is finicky. Oral semaglutide has to be taken on an empty stomach with no more than a few sips of water, followed by a 30-minute wait before eating, drinking, or taking other pills. Skipping that routine sharply cuts how much drug is absorbed.
Side effects and cautions are real. Nausea, vomiting, and diarrhea are common, especially at first. GLP-1 drugs are not for type 1 diabetes and are avoided in people with a personal or family history of medullary thyroid cancer or MEN2. Gallbladder problems and, rarely, pancreatitis can occur.
Cost and access. Brand-name GLP-1 medicines remain expensive and are not always covered. Benefits also depend on staying on the drug — as with the whole class, stopping tends to reverse the gains in weight and metabolic control over time.

Practical Takeaway

For someone living with both type 2 diabetes and heart failure, this analysis is a reason for cautious optimism — and a good prompt to ask your cardiologist or endocrinologist whether an oral GLP-1 medicine fits your treatment plan. It is not a signal for people without heart failure to start semaglutide expecting a cardiac payoff, and it does not replace the proven medicines used for the reduced-ejection-fraction form of the disease. As always, these are prescription decisions made with a clinician who knows your full history, not something to start or stop on your own. The larger message is a hopeful one: the tools we already use to manage blood sugar are increasingly turning out to protect the heart as well.

Sources

Pop-Busui R, et al. Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial. JAMA Internal Medicine. 2026;186(4):426–436. doi:10.1001/jamainternmed.2025.7774
Full article (JAMA Network): jamanetwork.com — SOUL heart-failure secondary analysis
PubMed record: PMID 41627802
Oregon Health & Science University news release (February 26, 2026): Oral semaglutide lowers risk of heart failure events in people with Type 2 diabetes
SOUL trial registration: ClinicalTrials.gov NCT03914326
PubMed topic search: oral semaglutide heart failure type 2 diabetes SOUL

Connections

Back to Table of Contents